These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63 related articles for article (PubMed ID: 8461397)
41. Anti-V beta TcR monoclonal antibodies identify and can activate anergic T cells from mice rendered neonatally tolerant of class II alloantigens. Levy RB; Jones M; Streilein JW Transplant Proc; 1993 Feb; 25(1 Pt 1):360-1. PubMed ID: 8438335 [No Abstract] [Full Text] [Related]
42. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition. Patel DM; Arnold PY; White GA; Nardella JP; Mannie MD J Immunol; 1999 Nov; 163(10):5201-10. PubMed ID: 10553040 [TBL] [Abstract][Full Text] [Related]
43. A mutant antigen-presenting cell defective in antigen presentation expresses class II MHC molecules with an altered conformation. Dang LH; Lien LL; Benacerraf B; Rock KL J Immunol; 1993 May; 150(10):4206-17. PubMed ID: 8482833 [TBL] [Abstract][Full Text] [Related]
44. Selective suppression of T-cell activation by administration of MHC class II-binding peptides. Adorini L Transplant Proc; 1992 Aug; 24(4 Suppl 2):14-6. PubMed ID: 1496683 [No Abstract] [Full Text] [Related]
45. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation. Hillman GG; Kallinteris NL; Lu X; Wang Y; Wright JL; Li Y; Wu S; Forman JD; Gulfo JV; Humphreys RE; Xu M Cancer Treat Rev; 2004 May; 30(3):281-90. PubMed ID: 15059651 [TBL] [Abstract][Full Text] [Related]
46. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy. Bonehill A; Heirman C; Thielemans K J Gene Med; 2005 Jun; 7(6):686-95. PubMed ID: 15693037 [TBL] [Abstract][Full Text] [Related]
47. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Holling TM; Schooten E; van Den Elsen PJ Hum Immunol; 2004 Apr; 65(4):282-90. PubMed ID: 15120183 [TBL] [Abstract][Full Text] [Related]
48. The use of class II MHC binding peptides in immunotherapy. Wraith DC Br J Rheumatol; 1991; 30 Suppl 2():14-6. PubMed ID: 1993249 [No Abstract] [Full Text] [Related]
49. Anti-class II antibody treatment in autoimmune diseases. Boitard C Immunol Ser; 1993; 59():279-93. PubMed ID: 8461393 [No Abstract] [Full Text] [Related]
50. Alternative pathways of T-cell activation and positive clonal selection. Patarca R; Singh RP; Wei FY; Iregui MV; Singh P; Schwartz J; Cantor H Immunol Rev; 1990 Aug; 116():85-100. PubMed ID: 1977691 [No Abstract] [Full Text] [Related]